Temsirolimus (also known as CCI-779) is a recently developed mTOR inhibitor, with improved aqueous solubility and more favorable pharmaceutical properties compared with the parent compound rapamycin. Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.

June 21, 2017

prudect name : Temsirolimus (also known as CCI-779) is a recently developed mTOR inhibitor, with improved aqueous solubility and more favorable pharmaceutical properties compared with the parent compound rapamycin.
Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.
Temsirolimus

Synonyms: Torisel,NSC-683864,CCI-779CAS NO: 162635-04-3Molecular Formula: C₅₆H₈₇NO₁₆Molecular Weight: 1030.29Purity: 98% minSolubility: In DMSOStorage: −20°C 2 years

web site: www.medchemexpress.com